Dinaciclib (SCH727965)

Potent CDK inhibitor CAS# 779353-01-4

Dinaciclib (SCH727965)

Catalog No. BCC3765----Order now to get a substantial discount!

Product Name & Size Price Stock
Dinaciclib (SCH727965): 5mg $58 In Stock
Dinaciclib (SCH727965): 10mg Please Inquire In Stock
Dinaciclib (SCH727965): 20mg Please Inquire Please Inquire
Dinaciclib (SCH727965): 50mg Please Inquire Please Inquire
Dinaciclib (SCH727965): 100mg Please Inquire Please Inquire
Dinaciclib (SCH727965): 200mg Please Inquire Please Inquire
Dinaciclib (SCH727965): 500mg Please Inquire Please Inquire
Dinaciclib (SCH727965): 1000mg Please Inquire Please Inquire
Related Products
  • CDK9 inhibitor 2

    Catalog No.:BCC1466
    CAS No.:1263369-28-3
  • AZD-5438

    Catalog No.:BCC3689
    CAS No.:602306-29-6
  • PHA-848125

    Catalog No.:BCC3839
    CAS No.:802539-81-7
  • AT7519

    Catalog No.:BCC2541
    CAS No.:844442-38-2
  • P276-00

    Catalog No.:BCC4415
    CAS No.:920113-03-7
  • SB1317

    Catalog No.:BCC1925
    CAS No.:937270-47-8

Quality Control of Dinaciclib (SCH727965)

Number of papers citing our products

Chemical structure

Dinaciclib (SCH727965)

3D structure

Chemical Properties of Dinaciclib (SCH727965)

Cas No. 779353-01-4 SDF Download SDF
PubChem ID 46926350 Appearance Powder
Formula C21H28N6O2 M.Wt 396.49
Type of Compound N/A Storage Desiccate at -20°C
Synonyms SCH 727965
Solubility DMSO : ≥ 56 mg/mL (141.24 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name 2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol
SMILES CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO
Standard InChIKey PIMQWRZWLQKKBJ-SFHVURJKSA-N
Standard InChI InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Dinaciclib (SCH727965)

DescriptionDinaciclib (SCH727965) is a novel and potent inhibitor of CDK for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively.
TargetsCDK2CDK5CDK1CDK9    
IC501 nM1 nM3 nM4 nM    

Protocol

Kinase experiment [1]:

Cyclin/CDK kinase assay

Recombinant cyclin/CDK holoenzymes were purified from Sf9 cells engineered to produce baculoviruses that express a specific cyclin or CDK. Cyclin/CDK complexes were typically diluted to a final concentration of 50 μg/mL in a kinase reaction buffer containing 50 mmol/L Tris-HCl (pH 8.0), 10 mmol/L MgCl2, 1 mmol/L DTT, and 0.1 mmol/L sodium orthovanadate. For each kinase reaction, 1 μg of enzyme and 20 μL of a 2-μmol/L substrate solution (a biotinylated peptide derived from histone H1; Amersham) were mixed and combined with 10 μL of diluted SCH 727965. The reaction was started by the addition of 50 μL of 2 μmol/L ATP and 0.1 μCi of 33P-ATP. Kinase reactions were incubated for 1 hour at room temperature and were stopped by the addition of 0.1% Triton X-100, 1 mmol/L ATP, 5 mmol/L EDTA, and 5 mg/mL streptavidin-coated SPA beads. SPA beads were captured using a 96-well GF/B filter plate and a Filtermate universal harvester. Beads were washed twice with 2 mol/L NaCl and twice with 2 mol/L NaCl containing 1% phosphoric acid. The signal was then assayed using a Top-Count 96-well liquid scintillation counter. Dose-response curves were generated from duplicate, eight-point serial dilutions of inhibitory compounds. IC50 values were derived by nonlinear regression analysis.

Cell experiment [1]:

Cell lines

A2780 cells

Preparation method

Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

2 h

Applications

SCH 727965 significantly abrogates phosphorylation of Rb on Ser 807/811 at concentrations >6.25 nmol/L and also leads to the generation of the p85 PARP cleavage product. 100 nmol/L SCH727965 treatment for 2 hours is effective in inducing suppression of Rb phosphorylation and caspase activation which can be detected up to 6 hours later.

Animal experiment [1]:

Animal models

A2780 ovarian cancer mouse xenograft model

Dosage form

i.p. administration at 8, 16, 32, and 48 mg/kg daily

Application

SCH 727965 i.p. administration at 8, 16, 32, and 48 mg/kg daily for 10 days shows tumor inhibitionby 70%, 70%, 89%, and 96%, respectively. SCH 727965 is also well tolerated, and the maximum body weight loss in the highest dosage group is 5%.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Parry D, Guzi T, Shanahan F et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010 Aug;9(8):2344-53.

Dinaciclib (SCH727965) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Dinaciclib (SCH727965) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Dinaciclib (SCH727965)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.5221 mL 12.6107 mL 25.2213 mL 50.4426 mL 63.0533 mL
5 mM 0.5044 mL 2.5221 mL 5.0443 mL 10.0885 mL 12.6107 mL
10 mM 0.2522 mL 1.2611 mL 2.5221 mL 5.0443 mL 6.3053 mL
50 mM 0.0504 mL 0.2522 mL 0.5044 mL 1.0089 mL 1.2611 mL
100 mM 0.0252 mL 0.1261 mL 0.2522 mL 0.5044 mL 0.6305 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Dinaciclib (SCH727965)

Dinaciclib is a potent cyclin-dependent kinase (CDK) inhibitor with IC50s for CDK2, CDK5, CDK1 and CDK9 at 1 nM, 1 nM, 3 nM, and 4 nM, respectively. [1] It is in phase I or II clinical trials for various cancers.

Dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. [2] Inhibition of CDK 1 suppresses Rb phosphorylation, leading to cell cycle arrest and apoptosis. [3]

Dinaciclib is active against a broad spectrum of human tumor cell lines in vitro and in vivo. It has great potential to improve cancer chemotherapy.

References:
[1]Parry D., et al. (2010). Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor. Mol Cancer Ther (9): 2344- 2353.
[2]Martin, M. P., et al. (2013). Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chemical Biology 8 (11): 2360–5.
[3]Payton M., et al. (2006). Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors. Cancer Res 66: 4299-4308.

Featured Products
New Products
 

References on Dinaciclib (SCH727965)

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.[Pubmed:21768779]

Cancer Biol Ther. 2011 Oct 1;12(7):598-609. Epub 2011 Oct 1.

Pancreatic cancer is one of the most lethal of human malignancies, and potent therapeutic options are lacking. Inhibition of cell cycle progression through pharmacological blockade of cyclin-dependent kinases (CDK) has been suggested as a potential treatment option for human cancers with deregulated cell cycle control. Dinaciclib (SCH727965) is a novel small molecule multi-CDK inhibitor with low nanomolar potency against CDK1, CDK2, CDK5 and CDK9 that has shown favorable toxicity and efficacy in preliminary mouse experiments, and has been well tolerated in Phase I clinical trials. In the current study, the therapeutic efficacy of SCH727965 on human pancreatic cancer cells was tested using in vitro and in vivo model systems. Treatment with SCH727965 significantly reduced in vitro cell growth, motility and colony formation in soft agar of MIAPaCa-2 and Pa20C cells. These phenotypic changes were accompanied by marked reduction of phosphorylation of Retinoblastoma (Rb) and reduced activation of RalA. Single agent therapy with SCH727965 (40 mg/kg i.p. twice weekly) for 4 weeks significantly reduced subcutaneous tumor growth in 10/10 (100%) of tested low-passage human pancreatic cancer xenografts. Treatment of low passage pancreatic cancer xenografts with a combination of SCH727965 and gemcitabine was significantly more effective than either agent alone. Gene Set Enrichment Analysis identified overrepresentation of the Notch and Transforming Growth Factor-beta (TGF-beta) signaling pathways in the xenografts least responsive to SCH727965 treatment. Treatment with the cyclin-dependent kinase inhibitor SCH727965 alone or in combination is a highly promising novel experimental therapeutic strategy against pancreatic cancer.

Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism.[Pubmed:24362465]

Mol Cancer Ther. 2014 Mar;13(3):662-74.

Evidence implicating dysregulation of the IRE1/XBP-1s arm of the unfolded protein response (UPR) in cancer pathogenesis (e.g., multiple myeloma) has prompted the development of IRE1 RNase inhibitors. Here, effects of cyclin-dependent kinase (CDK) inhibitor SCH727965 (dinaciclib) on the IRE1 arm of the UPR were examined in human leukemia and myeloma cells. Exposure of cells to extremely low (e.g., nmol/L) concentrations of SCH727965, a potent inhibitor of CDKs 1/2/5/9, diminished XBP-1s and Grp78 induction by the endoplasmic reticulum (ER) stress-inducers thapsigargin and tunicamycin, while sharply inducing cell death. SCH727965, in contrast to IRE1 RNase inhibitors, inhibited the UPR in association with attenuation of XBP-1s nuclear localization and accumulation rather than transcription, translation, or XBP-1 splicing. Notably, in human leukemia cells, CDK1 and 5 short hairpin RNA (shRNA) knockdown diminished Grp78 and XBP-1s upregulation while increasing thapsigargin lethality, arguing for a functional role for CDK1/5 in activation of the cytoprotective IRE1/XBP-1s arm of the UPR. In contrast, CDK9 or 2 inhibitors or shRNA knockdown failed to downregulate XBP-1s or Grp78. Furthermore, IRE1, XBP-1, or Grp78 knockdown significantly increased thapsigargin lethality, as observed with CDK1/5 inhibition/knockdown. Finally, SCH727965 diminished myeloma cell growth in vivo in association with XBP-1s downregulation. Together, these findings demonstrate that SCH727965 acts at extremely low concentrations to attenuate XBP-1s nuclear accumulation and Grp78 upregulation in response to ER stress inducers. They also highlight a link between specific components of the cell-cycle regulatory apparatus (e.g., CDK1/5) and the cytoprotective IRE1/XBP-1s/Grp78 arm of the UPR that may be exploited therapeutically in UPR-driven malignancies.

Description

Dinaciclib is a potent inhibitor of CDK, with IC50s of 1, 1, 3, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively.

Keywords:

Dinaciclib (SCH727965),779353-01-4,SCH 727965,Natural Products,Cyclin-Dependent Kinases, buy Dinaciclib (SCH727965) , Dinaciclib (SCH727965) supplier , purchase Dinaciclib (SCH727965) , Dinaciclib (SCH727965) cost , Dinaciclib (SCH727965) manufacturer , order Dinaciclib (SCH727965) , high purity Dinaciclib (SCH727965)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: